… According to rapid development of chemotherapy in advanced non-small cell lung cancer
(NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually since …

… includes a large number of patients. Therefore, two major Japanese societies dealing with
lung cancer, the Japan Lung Cancer Society and the Japanese Association for Chest Surgery…

… This study provides important information on ILD in an advanced/recurrent NSCLC setting
in Japanese patients in Japan, and it is the largest prospective study of this condition to date. …

… Patients One hundred and forty-one Japanese patients with untreated SCLC were diagnosed
between April 2006 and March 2011 at Kyoto University Hospital. Of these, 19 received …

… not been investigated in Japanese patients with NSCLC. It is important that targeted agents
that are established in Western patients are also studied in Japanese patients, as ethnic …

… genetic factors and clinical outcome in Japanese non-small-cell lung cancer (NSCLC)
patients treated with gefitinib. Ninety-eight NSCLC patients who had been treated with gefitinib, …

… Immunological and nutritional markers could be useful for predicting the outcomes of CIT
for Japanese patients with advanced non-small cell lung cancer. The timing of their evaluation …

… The test of PD-L1 expression has been covered by insurance from February 2017 in Japan,
but all of the early death patients in this study died by November 2016. In only 1 patient, the …

… subgroup analysis of Japanese patients in the LUX-Lung 3 trial to confirm if the efficacy
and safety of afatinib in Japanese patients were consistent with the overall patient population. …

… except in Japan, Korea and Taiwan compared nivolumab with docetaxel in patients with …
The present study evaluated the safety and efficacy of nivolumab in Japanese patients with …